Developing organoids from breast cancer tissue
Official title: Developing Breast (Cancer) Organoids
Run by Maastricht Radiation Oncology · NCT05317221 · Data updated 2026-11-12
This study is trying to create mini versions of breast cancer tumors from patient samples to see how they can help doctors understand the disease better and choose the best treatments for each person.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 60 (estimated) |
| Sponsor | Maastricht Radiation Oncology Academic / other |
| Locations | 1 site (Maastricht) |
| Status | Recruiting |
| Started | September 1, 2022 |
| Main results expected | April 1, 2028 |
| Study ends | May 1, 2028 |
| Registry record updated | May 12, 2026 |
| Trial ID | NCT05317221 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are female patients over 18 years old with a confirmed diagnosis of breast cancer who are undergoing primary surgery.
✕Probably not a fit
Patients who are physically or mentally incapable of providing informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to create a living biobank of breast cancer organoids derived from patient tissue samples collected during routine surgical procedures. By obtaining small samples of excised tumors and blood for genetic analysis, the study seeks to understand how these organoids reflect disease progression, treatment response, and relapse across different breast cancer subtypes. The goal is to develop a patient-tailored clinical model that addresses tumor heterogeneity and guides individualized treatment selection without altering the standard care process for participants.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for breast cancer patients.
How similar studies have gone: Other studies have shown promise in using organoids for drug response screening, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female, * \>18 years, * Family Anamneses * Breast cancer (proven by histopathology), Included subtypes; (ER-,PR- HER2-); (ER+, PR+, HER2-); (ER+, PR+ HER2+). * Primary surgery (lumpectomy or mastectomy) Exclusion Criteria: \- Physically or mentally incapable or incompetent to sign informed consent
Where it's running
-
Maastricht University Medical Center
Maastricht, Netherlands Recruiting
Study contacts
- Principal investigator: Marc Vooijs, PhD — Maastricht University
- Study coordinator: Chantal Overhof
- Email: chantal.overhof@maastro.nl
- Phone: +31 88 44 55 683
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.